CD274 and neoplasm: A second phase Ib study reported interesting results in terms of tolerance and antitumor activity in a population of patients with locally advanced or metastatic SCCA overexpressing PDL‐1 and receiving pembrolizumab after failure of at least one line of chemotherapy.13 These results are not very far from ours regarding the tumor response rate but appear to indicate an advantage in favor of immunotherapy in terms of PFS and OS.